Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 5 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 338 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar boomertom (48.49) Submitted: 9/30/2014 2:45:27 PM : Outperform Start Price: $106.22 GILD Score: +0.84

Superb company. Grossly undervalued.

Recs

0
Member Avatar qualityplustime (< 20) Submitted: 9/30/2014 2:12:57 AM : Outperform Start Price: $107.48 GILD Score: -0.07

GILD has begun to license Sovaldi (Hepititis C blockbuster) for sale in India and other large markets, I believe the earnings multiple will expand in Q4.

Recs

0
Member Avatar Googlespooch (23.96) Submitted: 9/29/2014 12:15:01 AM : Outperform Start Price: $107.59 GILD Score: -0.92

Strong HIV and Hep C portfolio. Impressive margins and growth prospects.

Recs

0
Member Avatar RugbyViking13 (86.16) Submitted: 9/27/2014 5:27:57 PM : Outperform Start Price: $107.59 GILD Score: -0.92

they make drugs that make money. Probably late to this party

Recs

0
Member Avatar Irish2014 (50.84) Submitted: 9/13/2014 9:23:38 AM : Outperform Start Price: $101.90 GILD Score: +6.04

Outperform due to Sovaldi utilization and other pipeline/expansion opportunities.

Recs

0
Member Avatar Morass (< 20) Submitted: 9/6/2014 9:14:03 PM : Outperform Start Price: $104.95 GILD Score: +3.88

GILD is a proven leader in biotech.

Recs

0
Member Avatar HILL6BILLY (20.44) Submitted: 9/5/2014 4:45:34 PM : Outperform Start Price: $104.95 GILD Score: +3.88

Earnings almost too good to be true......

Recs

0
Member Avatar calguy489 (20.25) Submitted: 9/2/2014 10:26:29 AM : Outperform Start Price: $108.47 GILD Score: +0.53

Great products

Recs

0
Member Avatar cipo (< 20) Submitted: 8/28/2014 9:56:02 AM : Outperform Start Price: $107.88 GILD Score: +0.59

the growth of free cash flow could lead to a successful dividend policy

Recs

0
Member Avatar warrenout (99.02) Submitted: 8/26/2014 8:33:10 PM : Underperform Start Price: $106.55 GILD Score: -2.13

Short-term short of a great company that's a bit ahead of itself at the moment

Recs

0
Member Avatar irondistance (< 20) Submitted: 8/25/2014 3:30:51 PM : Outperform Start Price: $107.20 GILD Score: +1.39

SOVALDI

Recs

0
Member Avatar Stigshift (20.23) Submitted: 8/22/2014 3:26:17 PM : Outperform Start Price: $74.85 GILD Score: +37.17

real money pick

Recs

0
Member Avatar Toady (< 20) Submitted: 8/2/2014 11:44:47 PM : Outperform Start Price: $92.00 GILD Score: +14.00

Creating products that CURE people not just treat them (Hep C). Strong company with solid fundamentals. Very cheap stock with a ton of room to grow. Look at their pipeline, this company cares about growth and increasing value to their shareholders.

Recs

0
Member Avatar mrfore4471 (38.15) Submitted: 7/30/2014 12:01:52 PM : Outperform Start Price: $93.71 GILD Score: +13.64

When you create a drug that totally cures (in 98% of cases) a disease such as hepititas C, you know you've done something good. I hesitate extending the time frame because there seems to be some competitors who will probably accomplish this and for a cheaper price. In any case one of the research firms thinks this stock could hit $140.00 which obviously is pretty good.

Recs

1
Member Avatar shotgun06 (< 20) Submitted: 7/23/2014 4:20:17 PM : Outperform Start Price: $91.56 GILD Score: +17.58

Look at the products that they have and have in trials. The need for these products are very large!

Recs

1
Member Avatar shroff33 (< 20) Submitted: 7/20/2014 5:01:33 PM : Outperform Start Price: $89.80 GILD Score: +18.97

GILD will prevail over competition from ABBV and MRK.

Recs

0
Member Avatar zzgorch (38.75) Submitted: 6/30/2014 2:13:05 PM : Outperform Start Price: $83.38 GILD Score: +27.50

Strong EPS, well below market Forward P/E (10.72) and a PEG well under one (0.46). Gilead is finding actual cures for nasty diseases (Hepatitis C) and has HUGE upside potential. Wish I had the funds to buy on the drop early this spring but there is plenty of room to run. It should get up to 100 by year end.

Recs

0
Member Avatar bdescent (69.25) Submitted: 6/27/2014 8:37:32 PM : Outperform Start Price: $82.79 GILD Score: +28.18

Nice pipeline.

Recs

0
Member Avatar rbitrage (53.76) Submitted: 6/22/2014 9:20:14 PM : Outperform Start Price: $81.27 GILD Score: +30.75

Sovaldi. In spite of the fact charging so much for a drug should be illegal, it isn't. Gilead recognizes this and making a mint. Sovaldi actually cures Hep-C (most of the time) and the bad press has been fantastic advertising. Our country might go broke paying for drugs like this, but in the meantime, companies like Gilead will be laughing- all the way to the bank.

Recs

0
Member Avatar Investinguppy (< 20) Submitted: 6/17/2014 11:01:54 PM : Outperform Start Price: $79.85 GILD Score: +32.48

Solvaldi will surprise to the upside and is first to market. Promising pipeline.

Featured Broker Partners


Advertisement